Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 5:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 840 matching trials from the live ClinicalTrials.gov search.
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Artificial Intelligence-based Intervention, Interview, Survey Administration
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 39 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Secondary Myelofibrosis
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, mycophenolate mofetil, tacrolimus, polymerase chain reaction, polymorphism analysis, flow cytometry, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Genetic + 2 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Lymphoma
Interventions
Gemcitabine, Busulfan, Melphalan, Stem Cell Transplantation, Palifermin
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 70 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Malignant Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Cancer Educational Materials, Follow-Up Care, Questionnaire
Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
7 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Conditions
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Undifferentiated Leukemia
Interventions
Cladribine, Cyclophosphamide, Cyclosporine, Cytarabine, Filgrastim, Hematopoietic Cell Transplantation, Mitoxantrone, Mycophenolate Mofetil, Mycophenolate Sodium, Total-Body Irradiation, Idarubicin, Fludarabine, Multigated Acquisition Scan, Echocardiography Test, X-Ray Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Multiple Myeloma
Interventions
Panobinostat
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Leflunomide, Placebo Administration
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Duarte, California
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Electronic Health Record Review, Spiritual Therapy, Survey Administration
Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Acute Leukemia, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Thrombocytopenia
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Hematopoietic Neoplasm, Malignant Solid Neoplasm, Lymphatic System Neoplasm
Interventions
Fitbit, Apple HealthKit-based devices
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia
Interventions
Total Body Irradiation, Thiotepa, Fludarabine, Rabbit ATG, Palifermin
Radiation · Drug · Biological
Lead sponsor
Sherif S. Farag
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
10 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Cytology Specimen Collection Procedure
Other
Lead sponsor
National Cancer Institute LAO
Other
Eligibility
2 Months and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
140
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Arroyo Grande, California + 95 more
Conditions
Acute Lymphocytic Leukemia
Interventions
Inotuzumab Ozogamicin
Drug
Lead sponsor
Leland Metheny
Other
Eligibility
16 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
7
States / cities
Westwood, Kansas • Boston, Massachusetts • Omaha, Nebraska + 3 more
Conditions
Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell
Interventions
Dexamethasone, Panobinostat, Liposomal vincristine, Mitoxantrone, Peg-asparaginase, Bortezomib, Intrathecal Triples, High-dose methotrexate, 6-Mercaptopurine, High-dose cytarabine, Nelarabine, Cyclophosphamide, Etoposide, Clofarabine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Adult Hodgkin Lymphoma, Adult Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Hodgkin Lymphoma, Childhood Myelodysplastic Syndrome, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Myelofibrosis, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Non-Hodgkin Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Sirolimus
Procedure · Other · Drug
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Lymphoma
Interventions
carmustine, cytarabine, etoposide, melphalan, peripheral blood stem cell transplantation, tositumomab and iodine I 131 tositumomab
Drug · Procedure · Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Malignant Solid Neoplasm, Chronic Lymphocytic Leukemia, Hematopoietic and Lymphatic System Neoplasm, Hodgkin Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma
Interventions
American Ginseng, Placebo Administration, Questionnaire Administration
Dietary Supplement · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
15
States / cities
Albert Lea, Minnesota • Bemidji, Minnesota • Brainerd, Minnesota + 12 more
Completed Phase 2 Interventional Results available

Allogeneic Transplant in HIV Patients (BMT CTN 0903)

NCT01410344
Conditions
Leukemia, Lymphoma, HIV
Interventions
Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine, Cyclophosphamide and Total Body Irradiation
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
15 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
11
States / cities
Phoenix, Arizona • Duarte, California • San Francisco, California + 8 more
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
aldesleukin, therapeutic allogeneic lymphocytes, therapeutic autologous lymphocytes, cytarabine, etoposide, mitoxantrone hydrochloride, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia
Interventions
Fludarabine, Fractionated total body irradiation, Busulfan, Cyclophosphamide, Single dose total body irradiation, Melphalan, Granulocyte-colony stimulating factor, Stem cell transplant, Azacitidine
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Functional Magnetic Resonance Imaging, Interview, Psilocybine, Psychotherapy, Questionnaire Administration
Procedure · Other · Drug + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Acute Leukemias of Ambiguous Lineage, Bacterial Infection, Diarrhea, Fungal Infection, Musculoskeletal Complications, Neutropenia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
levofloxacin
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
78
States / cities
Little Rock, Arkansas • Downey, California • Duarte, California + 65 more
Conditions
Chronic Lymphocytic Leukemia, Graft vs Host Disease, Leukemia, Myelodysplastic Syndrome, Myeloid Leukemia
Interventions
Blood cell transplantation
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
55 Years to 71 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland